HilleVax, Inc. (NASDAQ: HLVX)
$2.0650
-0.0250 ( +0.24% ) 77.3K
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
Market Data
Open
$2.0650
Previous close
$2.0900
Volume
77.3K
Market cap
$101.60M
Day range
$2.0250 - $2.0910
52 week range
$1.5500 - $20.2200
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 8-k | 8K-related | 11 | Dec 05, 2024 |
| 8-k | 8K-related | 13 | Nov 07, 2024 |
| 10-q | Quarterly Reports | 69 | Nov 07, 2024 |
| 8-k | 8K-related | 11 | Oct 16, 2024 |
| 8-k | 8K-related | 13 | Aug 09, 2024 |
| 10-q | Quarterly Reports | 72 | Aug 09, 2024 |
| 8-k | 8K-related | 11 | Jul 31, 2024 |
| 8-k | 8K-related | 11 | Jul 23, 2024 |
| 8-k | 8K-related | 13 | Jul 08, 2024 |
| 8-k | 8K-related | 12 | Jun 10, 2024 |